Pediatric stiff-person syndrome and related disorders: A systematic review

H Shafeeq Ahmed1, Purva Reddy Jayaram2, Deepika Reddy Aluru2

  • 1Bangalore Medical College and Research Institute, K.R Road, Bangalore, 560002, Karnataka, India. shafeeqahmed2002@gmail.com.

Insights

Pediatric stiff-person syndrome (SPS) presents diverse clinical features and comorbidities, including type 1 diabetes and thyroid issues. Treatment often involves benzodiazepines, with varying outcomes, highlighting the need for tailored management strategies.

Area of Science:

  • Neurology
  • Immunology
  • Pediatrics

Background:

  • Stiff-person syndrome (SPS) is a rare, complex neuromuscular autoimmune disorder.
  • Pediatric SPS cases present unique diagnostic and therapeutic challenges.
  • Limited understanding of pediatric SPS necessitates comprehensive analysis.

Purpose of the Study:

  • To systematically review and analyze the clinical profile of pediatric SPS.
  • To investigate comorbidities associated with pediatric SPS.
  • To evaluate treatment responses in pediatric SPS cases.

Main Methods:

  • Systematic review adhering to PRISMA guidelines.
  • Searched five databases up to March 2025 for pediatric SPS cases (age ≤ 20 years).
  • Analyzed data from 49 cases across 41 reports, covering demographics, symptoms, comorbidities, treatments, and outcomes.

Main Results:

  • 49 pediatric SPS cases identified globally, predominantly from the USA.
  • Common comorbidities include type 1 diabetes mellitus and thyroid dysfunction.
  • Benzodiazepines were the most frequent first-line therapy; corticosteroids, IVIG, and rituximab used adjunctively. Persistent symptoms occurred in 26.53% of cases.

Conclusions:

  • Pediatric SPS exhibits significant clinical heterogeneity and a clear autoimmune basis.
  • Findings support the autoimmune etiology of pediatric SPS.
  • A proposed treatment protocol is formulated to guide clinical management.
Abstract